Symptom Monitoring With Patient-Reported Outcomes During Curative-Intent Radiation Treatment
Practical Radiation Oncology · 2026-11
DOI: 10.1016/j.prro.2026.07.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2026-11. Verfasst von Ann C Raldow und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address…. Die Arbeit nennt 18 Literaturangaben. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
PURPOSE: Although symptom self-reporting improves clinical outcomes in patients with metastatic cancer receiving outpatient chemotherapy, the effects are not well established for patients undergoing radiation therapy (RT). In this randomized study, we assessed the impact of patient symptom self-reporting using the mobile Patient-Reported Outcomes version of the National Cancer Institute Common Terminology Criteria for Adverse Events Administration system (mPROS) application during curative-intent RT with concurrent chemotherapy for gastrointestinal, gynecological, lung, central nervous system, and head and neck cancers on health-related quality of life. METHODS AND MATERIALS: Enrolled patients were randomly assigned to symptom self-reporting with mPROS (experimental [EXP]) or usual care (control [CON]). EXP arm participants were asked to report symptoms at least weekly; severe or worsening symptoms triggered alerts to the clinical team. Participants remained in the study until 3 months after completion of RT. The Patient-Reported Outcomes Measurement Information System - 29 (PROMIS-29) was administered at baseline, completion of RT (end-of-treatment [EOT]), and 3 months after RT completion. Patient assessment of the usefulness of mPROS was measured via a 24-question exit survey using a 7-point Likert scale. RESULTS: There were 59 subjects enrolled, of which 55 (n = 28 EXP and n = 27 CON; mean age, 62.0 years; 69.1% male) completed at least 1 PROMIS-29. On average, EXP participants logged symptoms twice per week, with a mean of 15 severe attributes and 11 unique symptoms reported. There were no significant differences between mean changes in PROMIS-29 physical (EXP, ∆ -6.03 vs CON ∆ -4.04; P = .45) or mental (EXP ∆ -2.82 vs CON ∆ -2.17; P = .78) function scores from baseline to EOT. Likewise, there were no significant differences between median changes in PROMIS-29 physical (EXP ∆ -3.87 vs CON ∆ -2.22; P = .29) or mental (EXP ∆ -1.74 vs CON ∆ -1.39; P = .77) function scores from baseline to EOT. On multivariable linear regression adjusting for age, sex, race, ethnicity, and education, treatment arm was not a statistically significant predictor of physical [F(1,30) = 0.81; P = .38] or mental [F(1,30) = 0.00; P = .98] health scores at EOT. On the exit survey, mean scores for selected questions descriptively indicated high satisfaction and were as follows: care team understanding symptoms (6.27), feeling more involved in care (6.36), help with symptom tracking (6.18), and recommending mPROS to other patients (6.09). CONCLUSIONS: Use of mPROS to monitor symptoms, compared with usual care, did not result in statistically significant differences in physical or mental health-related quality of life. However, patients in the EXP group expressed high satisfaction with self-reporting, feeling more engaged in their cancer care, and helping them keep track of symptoms.
Autor:innen und Institutionen
- Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Electronic address: araldow@mednet.ucla.edu.
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
- Blue Halo, Inc, Germantown, Maryland.
Förderung
- National Cancer Institute
Zitieren
APA
Raldow, A. C., Lee, P., Chun, S. G., Gilliland, J., Hegde, J. V., Kishan, A. U., Odwuor, A. A., Ramakrishnan, S., Tate, M., Underwood, J., Xiang, M., Tsai, J., Atkinson, T. M., & Chen, A. B. (2026). Symptom Monitoring With Patient-Reported Outcomes During Curative-Intent Radiation Treatment. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2026.07.010
Vancouver
Raldow AC, Lee P, Chun SG, Gilliland J, Hegde JV, Kishan AU, et al. Symptom Monitoring With Patient-Reported Outcomes During Curative-Intent Radiation Treatment. Practical Radiation Oncology. 2026. doi:10.1016/j.prro.2026.07.010
BibTeX
@article{Raldow2026,
author = {Raldow, Ann C and Lee, Percy and Chun, Stephen G and Gilliland, Jaime and Hegde, Jay V and Kishan, Amar U and Odwuor, Abigael A and Ramakrishnan, Sridhar and Tate, Molly and Underwood, Jody and Xiang, Michael and Tsai, Jillian and Atkinson, Thomas M and Chen, Aileen B},
title = {Symptom Monitoring With Patient-Reported Outcomes During Curative-Intent Radiation Treatment},
journal = {Practical Radiation Oncology},
year = {2026},
doi = {10.1016/j.prro.2026.07.010}
}
EUVIMED